Integrated Investment Consultants LLC Purchases Shares of 16,104 CVS Health Co. (NYSE:CVS)

Integrated Investment Consultants LLC acquired a new position in CVS Health Co. (NYSE:CVS) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 16,104 shares of the pharmacy operator’s stock, valued at approximately $1,013,000.

Several other institutional investors also recently bought and sold shares of the stock. Assetmark Inc. increased its position in shares of CVS Health by 9.7% in the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock valued at $25,781,000 after acquiring an additional 36,132 shares during the period. Cullinan Associates Inc. grew its position in shares of CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock worth $7,125,000 after buying an additional 37,395 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of CVS Health during the second quarter valued at approximately $57,584,000. Oppenheimer Asset Management Inc. lifted its stake in CVS Health by 5.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 448,323 shares of the pharmacy operator’s stock worth $28,191,000 after acquiring an additional 24,285 shares during the period. Finally, CX Institutional increased its position in CVS Health by 698.0% during the 3rd quarter. CX Institutional now owns 74,609 shares of the pharmacy operator’s stock valued at $4,691,000 after purchasing an additional 65,259 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Price Performance

CVS opened at $57.07 on Friday. The company’s 50-day simple moving average is $59.20 and its two-hundred day simple moving average is $58.60. CVS Health Co. has a 52-week low of $52.71 and a 52-week high of $83.25. The stock has a market capitalization of $71.81 billion, a P/E ratio of 14.48, a P/E/G ratio of 0.94 and a beta of 0.55. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. During the same quarter last year, the company posted $2.21 earnings per share. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, analysts predict that CVS Health Co. will post 5.43 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were paid a dividend of $0.665 per share. The ex-dividend date was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.66%. CVS Health’s dividend payout ratio is currently 67.51%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Barclays cut their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Truist Financial restated a “buy” rating and issued a $67.00 target price (down previously from $76.00) on shares of CVS Health in a research note on Wednesday. Evercore ISI upped their price target on CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, TD Cowen upgraded shares of CVS Health from a “hold” rating to a “buy” rating and upped their price objective for the stock from $59.00 to $85.00 in a report on Friday, October 4th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $72.28.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.